<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515577</url>
  </required_header>
  <id_info>
    <org_study_id>17-001885</org_study_id>
    <secondary_id>NCI-2018-00546</secondary_id>
    <secondary_id>17-001885</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <nct_id>NCT03515577</nct_id>
  </id_info>
  <brief_title>Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery</brief_title>
  <acronym>PSMA vs AXUMIN</acronym>
  <official_title>Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial compares how well gallium 68-labeled PSMA-11 positron emission
      tomography/computed tomography (PET/CT) works compared to fluciclovine F18 PET/CT in imaging
      participants with prostate cancer after surgery that has come back. PET is an established
      imaging technique that uses small amounts of radioactivity and CT images provide an exact
      outline of organs and potential inflammatory tissue where it occurs in the body. Diagnostic
      procedures, such as PET/CT with gallium 68-labeled PSMA-11, may work better than PET/CT with
      fluciclovine F18 in helping find out how far the prostate cancer has spread.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the detection rates of gallium 68-labeled PSMA-11 ([68]Ga-PSMA-11) PET/CT and
      fluciclovine F18 (Axumin) PET/CT for the identification of tumor location(s), by patient and
      region based analysis.

      SECONDARY OBJECTIVES:

      I. Detection rate on a per-patient basis of (68)Ga-PSMA-11 PET/CT and Axumin PET/CT,
      stratified by prostate-specific antigen (PSA) value (0.2 - &lt; 0.5; 0.5 - &lt; 1.0; 1.0 - &lt; 2.0).

      II. Sensitivity and positive predictive value (PPV) on a per-patient basis, of (68)Ga-PSMA-11
      PET/CT and Axumin PET/CT for the detection of tumor location(s), confirmed by
      histopathology/biopsy and/or clinical and conventional imaging follow-up.

      III. Agreement among the readers, separate for (68)Ga-PSMA-11 PET/CT versus Axumin PET/CT.

      OUTLINE:

      Participants receive (68)Ga-PSMA-11 intravenously (IV) and 60-90 minutes later, undergo
      PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT
      within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.

      After completion of the PET/CT scan, participants are followed up between 1 and 3 days and up
      to 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">March 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gallium 68-labeled PSMA-11 ([68]Ga-PSMA-11) and fluciclovine F18 (Axumin) detection rates</measure>
    <time_frame>Up to 15 months: through data analysis completion (anonymized central imaging read), an estimation of 3 months after enrollment completion.</time_frame>
    <description>Will compare rates for the identification of tumor location(s), assessed by patient and region based analysis. This will be calculated and reported along with the corresponding two-sided 95% confidence intervals. The confidence intervals will be constructed using the Wilson score method. Detection rate in the per-participant analysis is defined as number of participants with PET positive disease, independent of pathology or imaging/clinical follow-up. Detection rate in the per-region analysis is defined as number of regions (prostate bed, pelvic lymph-nodes, extra-pelvic lymph-nodes, bone metastases, other soft tissue) resulted PET positive, independent of pathology or imaging/clinical follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection rates on a per-patient basis of 68^Ga-PSMA-11 PET and Axumin PET</measure>
    <time_frame>Up to 1 year after completion of PET/CT with 68^Ga-PSMA-11</time_frame>
    <description>This will be stratified by prostate-specific antigen (PSA) value (0.2 - &lt; 0.5, 0.5 - &lt; 1.0, 1.0 - &lt; 2.0, 2.0 - &lt; 5.0, ≥ 5.0) and will be summarized in tabular format and compared between PSA using chi-square analysis. Detection rate is defined as number of participants with PET positive disease, independent of pathology, imaging or clinical follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and PPV by-participant and region-based analysis of 68^Ga-PSMA-11 PET and Axumin PET for detection of tumor location(s)</measure>
    <time_frame>Up to 1 year after completion of PET/CT with 68^Ga-PSMA-11</time_frame>
    <description>The sensitivity and positive predictive values (PPV) will be calculated and reported along with the corresponding two-sided 95% confidence intervals. The confidence intervals will be constructed using the Wilson score method. Only participants having histopathology/biopsy and/or clinical and conventional imaging follow-up will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-observer (reader) agreement</measure>
    <time_frame>Up to 15 months: through data analysis completion (anonymized central imaging read), an estimation of 3 months after enrollment completion.</time_frame>
    <description>Agreement will be calculated separately for 68^Ga-PSMA-11 PET/CT versus Axumin PET/CT. For binary data, agreement among central readers will be evaluated using Fleiss' k. For non-binary data with more than ten observations, agreement among central readers will be evaluated by interclass correlation coefficient (ICC). Ninety-five percent confidence intervals (CIs) will be reported for k and ICC values. Interpretation of k and ICC will be based on a classification provided by Landis and Koch: 0.0, poor; 0.0-0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; 0.81-1.00, almost-perfect reproducibility.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluciclovine F18</intervention_name>
    <description>Given fluciclovine F18</description>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
    <other_name>(18F)Fluciclovine</other_name>
    <other_name>(18F)GE-148</other_name>
    <other_name>18F-Fluciclovine</other_name>
    <other_name>[18F]FACBC</other_name>
    <other_name>Anti-(18f)FABC</other_name>
    <other_name>Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid</other_name>
    <other_name>Anti-[18F] FACBC</other_name>
    <other_name>Axumin</other_name>
    <other_name>Fluciclovine (18F)</other_name>
    <other_name>FLUCICLOVINE F-18</other_name>
    <other_name>GE-148 (18F)</other_name>
    <other_name>GE-148 F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically proven prostate cancer (PCa)

          -  Radical prostatectomy as definitive treatment for PCa

          -  Proven biochemical recurrence as defined by American Urological Association (AUA)
             recommendation: PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks
             after radical prostatectomy

          -  PSA values ranging from 0.2 ng/mL to 2 ng/mL

          -  No prior salvage therapies (including salvage radiotherapy and/or salvage lymph node
             dissection)

          -  Axumin PET/CT scan already performed or scheduled as best standard of care procedure
             for suspected disease relapse within 2 weeks before or after intended 68Ga-PSMA-11
             PET/CT

          -  Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group
             (ECOG)/World Health Organization [WHO] equivalent)

          -  Ability to understand a written informed consent document and the willingness to sign
             it

        Exclusion Criteria:

          -  Any change in prostate cancer treatment between Axumin and 68Ga-PSMA PET/CT scan

          -  Unable to lie flat, still or tolerate a PET scan
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannine Gartmann</last_name>
    <phone>310-206-7008</phone>
    <email>JGartmann@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Gartmann</last_name>
      <phone>310-206-7008</phone>
      <email>JGartmann@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Johannes Czernin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

